Lecanemab, an experimental dementia drug, slowed cognitive decline by 27% in late-stage clinical trials.
- Associate Professor in Dementia Neurology, University of Bristol
Contact Elizabeth for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Website
- Article Feed
- Joined
